The role of IFN-γ Elispot assay in HIV vaccine research

Nature Protocols

Volumn 4, Issue 4, 2009, Pages 461-469

  Streeck, Hendrik ^a,b   Frahm, Nicole ^a,b   Walker, Bruce D ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANALYTIC METHOD; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; IMMUNOASSAY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SCREENING TEST; VALIDATION PROCESS;

AIDS VACCINES; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIV; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; RESEARCH;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 64749112680     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2009.7     Document Type: Article

References (35)

1. Koup, R.A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
2. Schmitz, J.E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857-860 (1999).
3. Sáez-Cirión, A. et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. USA 104, 6776-6781 (2007).
4. Jin, X. et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
5. Borrow, P., Lewicki, H., Hahn, B.H., Shaw, G.M. & Oldstone, M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110 (1994).
6. Plata, F. et al. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature 328, 348-351 (1987).
7. Walker, B.D. et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328, 345-348 (1987).
8. Price, D.A. et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94, 1890-1895 (1997).
9. Allen, T.M. et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407, 386-390 (2000).
10. Carrington, M. & O'Brien, S.J. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54, 535-551 (2003).
11. Streeck, H. et al. Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J. Virol. 81, 7725-7731 (2007).
12. Altfeld, M. et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cel response against HIV-1. PLoS Med. 3, e403 (2006).
13. Czerkinsky, C. et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 110, 29-36 (1988).
14. Czerkinsky, C.C., Nilsson, L.A., Nygren, H., Ouchterlony, O. & Tarkowski, A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods 65, 109-121 (1983).
15. Schmittel, A., Keilholz, U. & Scheibenbogen, C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods 210, 167-174 (1997).
16. Sun, Y. et al. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J. Immunol. Methods 272, 23-34 (2003).
17. Hill, P.C. et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 4, e192 (2007).
18. Kester, K.E. et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26, 2191-2202 (2008).
19. Pass, H.A., Schwarz, S.L., Wunderlich, J.R. & Rosenberg, S.A. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 4, 316-323 (1998).
20. Lauer, G.M. et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J. Virol. 79, 12979-12988 (2005).
21. Wang, Z.Y., Okita, D.K., Howard, J. Jr. & Conti-Fine, B.M. Th1 epitope repertoire on the alpha subunit of human muscle acetylcholine receptor in myasthenia gravis. Neurology 48, 1643-1653 (1997).
22. Frahm, N. et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7, 173-178 (2006).
23. Frahm, N. et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J. Virol. 78, 2187-2200 (2004).
24. Cox, J.H. et al. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retroviruses 21, 68-81 (2005).
25. Horton, H. et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J. Immunol. Methods 323, 39-54 (2007).
26. Betts, M.R. et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107, 4781-4789 (2006).
27. Boulet, S. et al. A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses. J. Immunol. Methods 320, 18-29 (2007).
28. McElrath, M.J. et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 372 1894-1905 (2008).
29. Sekaly, R.P. The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development? J. Exp. Med. 205, 7-12 (2008).
30. Streeck, H. et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med. 5, e100 (2008).
31. Bailey, J.R. et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J. Virol. 82, 7395-7410 (2008).
32. Addo, M.M. et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77, 2081-2092 (2003).
33. Gnann, J.W. Jr., Nelson, J.A. & Oldstone, M.B. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J. Virol. 61, 2639-2641 (1987).
34. Addo, M.M. et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. USA 98, 1781-1786 (2001).
35. Bihl, F.K. et al. Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti-CD3 mAb T-cell expansion and 'RecycleSpot'. J. Transl. Med. 3, 20 (2005).